Granules India Limited · NSE:GRANULES
Granules India — Q1 FY2025 Earnings Presentation
34 slides from Granules India's earnings presentation, Jul 30, 2024
Slide 1: Filing cover letter to stock exchanges
© GRANULES REGISTERED OFFICE GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad - 500 081, Telangana, India. Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com CIN: L24110TG1991PLC012471 Date: July 30, 2024 To, National Stock Exchange o
Slide 2: Earnings Presentation - Q1FY25
Granules India Limited Earnings Presentation - Q1FY25 30th July 2024 1
Slide 3: Safe Harbour Statement
Safe Harbour Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendatio
Slide 4: Key business highlights for Q1 FY25
Key business highlights for Q1 FY 25 ▪ Strong gross margin for the quarter ▪ Continued growth in formulations share in the business ▪ Continued growth in North America region ▪ Decline in the Para API/ PFI sales due to higher customer inventory and price erosion ▪ Continued prioritization and invest
Slide 5: Quarterly Performance
Quarterly Performance Q1 FY 25 Earnings Presentation - Q1 FY 25 © 2024 Granules India Limited 4
Slide 6: Q1FY25 P&L: Y-o-Y Performance highlights
Q1FY25 P&L: Y-o-Y Performance highlights (In ₹ Mn) Q1 FY25 Q1 FY24 Y-o-Y Gr% Remarks on Y-o-Y performance Driven by formulations growth. Revenue 11,799 9,855 20% Q1 FY24 had lower base due to cyber incident Value Added 6,954 5,063 Achieved a higher value-added percentage compared to 37% Q1-FY24, att
Slide 7: Q1FY25 P&L: Q-o-Q Performance highlights
Q1FY25 P&L: Q-o-Q Performance highlights (In ₹ Mn) Q1 FY25 Q4 FY24 Q-o-Q Gr% Remarks on Q-o-Q performance Revenue Continued growth in FD segment offset by decline in Para 11,799 11,758 0.3% API/PFI sales volume, and price erosion Value Added 6,954 7,062 -1.5% Lower VA%, Q-o-Q, is attributed to produ
Slide 8: Q1FY25: Revenue split by Segments and Market
Q1FY25 : Revenue spilt by Segments and Market (In ₹ Mn) Division wise share Region wise share Q1 FY24 Q1 FY25 Y-o-Y Gr% Q1 FY24 Q1 FY25 Y-o-Y Gr% API 3,000 1,890 (37%) North America 6,017 8,700 45% PFI 1,482 997 (33%) Europe 2,405 1,493 (38%) FD 5,373 8,912 66% LATAM 481 535 11% India 504 569 13% RO
Slide 9: Q1FY25 Cashflow and Ratios: Q-o-Q highlights
Q1FY25 Cashflow and Ratios : Q-o-Q highlights (In ₹ Mn) Q1 Q4 Q1 Q4 Q1 Q4 FY25 FY24 FY25 FY24 FY25 FY24 Fixed Net debt/ ROCE% 19.6% 16.5% asset turn 1.74 1.77 EBITDA 0.77x 0.98x Increase in EBIT Slightly lower due to continued investment in Net debt decrease by Rs.481 Mn new project - Granules Life
Slide 10: Historical Performance
Historical Performance Earnings Presentation - Q1 FY 25 © 2024 Granules India Limited 9
Slide 11: Sales and profitability: Last 6 quarters historical performance
Sales and profitability : Last 6 quarters historical performance (In ₹ Mn) Sales VA and VA% EBITDA and EBITDA % PAT and PAT % Earnings Presentation - Q1 FY 25 © 2024 Granules India Limited 10 10
Slide 12: Cashflow and Ratios: Last 6 quarters historical performance
Cashflow and Ratios: Last 6 quarters historical performance (In ₹ Mn) ROCE% Asset turns Net debt and Net debt/EBITDA Working Capital days Operating Cash flow Capex Earnings Presentation - Q1 FY 25 © 2024 Granules India Limited 11 11
Slide 13: Sales and profitability: Last 5 years historical performance
Sales and profitability : Last 5 years historical performance (In ₹ Mn) Sales VA and VA% EBITDA and EBITDA % PAT and PAT % Earnings Presentation - Q1 FY 25 © 2024 Granules India Limited 12 12
Slide 14: Cashflow and Ratios: Last 5 years historical performance
Cashflow and Ratios: Last 5 years historical performance (In ₹ Mn) ROCE% Asset turns Net debt and Net debt/EBITDA Working Capital days Operating Cash flow Capex Earnings Presentation - Q1 FY 25 © 2024 Granules India Limited 13 13
Slide 15: ANDA/Dossier filing status
ANDA/Dossier filing status Earnings Presentation - Q1 FY 25 © 2024 Granules India Limited 14
Slide 16: Granules at a glance
Granules at a glance Earnings Presentation - Q1 FY 25 © 2024 Granules India Limited 15
Slide 17: Granules Purpose, Vision & Values
Granules Purpose, Vision & Values Earnings Presentation - Q1 FY 25 © 2024 Granules India Limited 16
Slide 18: An Illustrious Journey Spanning Four Decades
An Illustrious Journey Spanning Four Decades Building A World Class, Vertically Integrated Pharmaceutical Manufacturing Platform From being a paracetamol API manufacturing facility to a multi-faceted global pharmaceutical company, we have consistently achieved manufacturing success, set new standard
Slide 19: Manufacturing Network & Capacity
Manufacturing Network & Capacity Earnings Presentation - Q1 FY 25 © 2024 Granules India Limited 18
Slide 20: Business Strategy Update
Business Strategy Update Earnings Presentation - Q1 FY 25 © 2024 Granules India Limited 19
Slide 21: Strategy In Action: Moving up the value-chain and Product Diversification
Strategy In Action: Moving up the value-chain and Product Diversification Earnings Presentation - Q1 FY 25 © 2024 Granules India Limited 20
Slide 22: Strategy In Action: Strengthening Business in North America
Strategy In Action: Strengthening Business in North America Unique Manufacturing Platform of Optimizing “Make in India” (GIL) and “Make in America” (GPI , GPAK) Market leadership in CNS/ADHD (GPI operations), adding to the leadership position in large volume molecules GPI Market leadership: 7 produc
Slide 23: Strategy In Action: Portfolio Expansion
Strategy In Action: Portfolio Expansion Earnings Presentation - Q1 FY 25 © 2024 Granules India Limited 22
Slide 24: Strategy In Action: Building R&D Capability and Product Pipeline
Strategy In Action: Building R&D Capability and Product Pipeline Integrated Product Development # Scientists Genome Valley – MN Park 397 Across API & FD R&D R&D facility for Integrated Product Development ▪ Fast tracking product development through seamless coordination & shared analytical resource
Slide 25: Strategy In Action: Building & Sustaining Key Product Leadership
Strategy In Action: Building & Sustaining Key Product Leadership Key Operations and R&D Initiatives to Strengthen and Sustain Our Cost and Market Leadership Backward Integration Process Improvement Formulation Technologies Bio Catalysis + Cont. Mfg. Minimizing Carbon Footprint Earnings Presentation
Slide 26: Strategy In Action: Expanding Reach Through Commercial Excellence
Strategy In Action: Expanding Reach Through Commercial Excellence Replicate commercial success of North America in other key markets Strengthening Teams | Building Commercial Excellence Processes ▪ Revamped and augmented Commercial leadership team ▪ Formulation Driven Growth in Europe through key pa
Slide 27: Sustainability at Granules
Sustainability at Granules Earnings Presentation - Q1 FY 25 © 2024 Granules India Limited 26
Slide 28: Sustainability at Granules: Green Molecule Platform
Sustainability at Granules : Green Molecule Platform, beginning with our core products – Paracetamol & Metformin Granules CZRO has initiated a pilot DCDA plant in Visakhapatnam. The pilot plant has commenced operations in the month of March’24. Earnings Presentation - Q1 FY 25 © 2024 Granules India
Slide 29: Sustainability at Granules: Supply Chain Decarbonization of Pharmaceuticals
Sustainability at Granules : Pioneering Innovation for Complete Supply Chain Decarbonization of Pharmaceuticals Earnings Presentation - Q1 FY 25 © 2024 Granules India Limited 28
Slide 30: GHG Emission Disclosure
GHG Emission Disclosure Our emission disclosures for FY 23 has been updated during FY 24 disclosure cycle to include emissions for all our subsidiaries and now includes disclosure of our comprehensive scope 3 emissions in addition to previously disclosed Scope 1 and Scope 2 emissions. Granules scope
Slide 31: Sustainability at Granules: Adopting Green Chemistry and Sustainable Formulation manufacturing
Sustainability at Granules : Adopting Green Chemistry and Sustainable Formulation manufacturing Earnings Presentation - Q1 FY 25 © 2024 Granules India Limited 30
Slide 32: Social Impact Initiative: Pharma Pathshala at Swarna Bharat Trust
Social Impact Initiative : Pharma Pathshala at Swarna Bharat Trust Granules initiative to train a rural workforce through the Swarna Bharat Trust Earnings Presentation - Q1 FY 25 © 2024 Granules India Limited 31
Slide 33: Earnings Presentation - Q1 FY 25 © 2024 Granules India Limited
Earnings Presentation - Q1 FY 25 © 2024 Granules India Limited 32
Slide 34: Corporate address and investor relations contact
For investor relation – Granules IR desk Email: investorrelations@granulesindia.com www.granulesindia.com Ms. Payal Dave payal.dave@linkintime.co.in Mr. Irfan Raeen +91 97737 78669 532482 Irfan.raeen@linkintime.co.in GRANULES www.orientcap.com GRAN:IN GRAN:NS Corporate address: Floor 2 Block 3 My Ho